For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 6, 2026.
Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.5
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 6, 2026.
Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
Disclosure information is available at the beginning of the video presentation.
816 Listeners
5 Listeners
17 Listeners
3 Listeners
4 Listeners
10 Listeners
5 Listeners
28 Listeners
3 Listeners
2 Listeners
4 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
3,849 Listeners
42 Listeners
2 Listeners
111 Listeners
799 Listeners
12 Listeners
2 Listeners
60 Listeners
22 Listeners
181 Listeners
40 Listeners